All the news Showing 10 of 11 articles from: Hepatitis deltaGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Bulevirtide leads to sustained improvement for people with hepatitis D Liz Highleyman / 28 June 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... Bulevirtide for hepatitis D proves effective in real-world studies Liz Highleyman / 25 January 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load and improved liver enzyme levels in real-world studies in France and Austria, according to findings presented ... Bulevirtide appears safe and effective for hepatitis D Liz Highleyman / 28 June 2021 The entry inhibitor bulevirtide (Hepcludex) suppressed hepatitis delta viral load and improved liver enzyme levels in a phase III clinical trial, according to late-breaking study results presented this week at the 2021 International Liver ... Bulevirtide shows promise as maintenance therapy for hepatitis D Liz Highleyman / 30 August 2020 High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ... Combination therapies show promise against hepatitis D Liz Highleyman / 16 December 2019 Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ... Lonafarnib lowers hepatitis delta levels with acceptable side-effects Liz Highleyman / 27 January 2017 The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal ... Prenylation inhibitor lonafarnib lowers hepatitis delta viral load during therapy Liz Highleyman / 22 May 2015 Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log10 in a phase 2 study presented at the European Association for ... Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta Liz Highleyman / 15 May 2015 The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European ... Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... Hepatitis delta virus co-infection increases risk of poor liver-related outcomes for people living with HIV Michael Carter / 07 April 2014 Co-infection with hepatitis delta virus (HDV) is a major risk factor for hepatic decompensation and liver-related death in people living with HIV, Spanish investigators report in the online edition of Clinical Infectious Diseases. Over ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive